Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexofenadine in Parkinson's Disease
NCT06785298Phase 3Recruiting
- Sponsor
- Tanta University
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of fexofenadine in Parkinson's disease (PD) (2 arms), sponsored by Tanta University. Primary endpoint: Unified Parkinson's Disease Rating Scale at 6 months. Started Dec 2024; status: recruiting.
02
Drugs
fexofenadine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06785298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06785298.